James Kihara Sells 4,000 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 4,000 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $22.50, for a total value of $90,000.00. Following the completion of the transaction, the insider now owns 20,395 shares in the company, valued at $458,887.50. This represents a 16.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

James Kihara also recently made the following trade(s):

• On Friday, May 2nd, James Kihara sold 1,327 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $14.60, for a total transaction of $19,374.20.
• On Tuesday, April 8th, James Kihara sold 1,028 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $14.82, for a total transaction of $15,234.96.
• On Wednesday, March 26th, James Kihara sold 1,095 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $17.05, for a total transaction of $18,669.75.
• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $19.96, for a total transaction of $9,481.00.

ACADIA Pharmaceuticals Trading Down 1.2%

NASDAQ:ACAD traded down $0.27 during trading hours on Monday, hitting $21.99. 4,053,965 shares of the company traded hands, compared to its average volume of 1,928,461. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of 28.19 and a beta of 0.47. The firm has a 50-day moving average of $16.01 and a 200 day moving average of $17.16. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.40 and a twelve month high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. The company had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The company’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter last year, the company earned $0.10 EPS. Equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Exchange Traded Concepts LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 1st quarter valued at $29,000. Banque Transatlantique SA acquired a new position in ACADIA Pharmaceuticals in the first quarter worth about $31,000. Picton Mahoney Asset Management bought a new position in ACADIA Pharmaceuticals during the first quarter worth about $32,000. Federated Hermes Inc. boosted its holdings in ACADIA Pharmaceuticals by 231.5% during the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,618 shares in the last quarter. Finally, Virtus Fund Advisers LLC bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter valued at approximately $39,000. 96.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

ACAD has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft initiated coverage on ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price on the stock. UBS Group cut their price objective on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, April 28th. Robert W. Baird boosted their target price on ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Monday. HC Wainwright increased their price target on ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the company a “buy” rating in a report on Monday. Finally, Needham & Company LLC lifted their price target on shares of ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.42.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.